Next Article in Journal
Applying Broadband Dielectric Spectroscopy (BDS) for the Biophysical Characterization of Mammalian Tissues under a Variety of Cellular Stresses
Next Article in Special Issue
Selective Expression of Flt3 within the Mouse Hematopoietic Stem Cell Compartment
Previous Article in Journal
Potential Role of Free Fatty Acids in the Pathogenesis of Periodontitis and Primary Sjögren’s Syndrome
Previous Article in Special Issue
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(4), 837; doi:10.3390/ijms18040837

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

1
Instituto Português de Oncologia de Lisboa (IPOL), 1200-795 Lisbon, Portugal
2
Institut Paoli Calmettes, Marseille, France and Yale New Haven Hospital, New Haven, CT 06512, USA
3
Hopital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Diderot University, 75010 Paris, France
4
Hospital Universitario de Leon, 24071 Leon, Spain
5
University Hospital of Halle, 06120 Halle, Germany
6
Rush University Medical Center, Chicago, IN 60612, USA
7
Hospital Sao Joao, 4200-319 Porto, Portugal
8
University Tor Vergata, 00173 Rome, Italy
9
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
10
RCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero in Vulture (Pz), Italy
11
Department of Hematology VU University Medical Center, 1081 HV Amsterdam, The Netherlands
12
Centro Hospitalar Lisboa Norte Hospital Santa Maria, 1649-035 Lisbon, Portugal
13
Department of Internal Medicine IV, Hospital Wels-Grieskirchen, 4600 Wels, Austria
14
Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, 6020 Innsbruck, Austria
15
1st Department of Internal Medicine, Center for Oncology and Hematology, Wilhelminenspital, 1160 Vienna, Austria
16
Internal Medicine, Hospital Feldkirch,6800 Feldkirch, Austria
17
Department of Internal Medicine, Hospital Fürstenfeld, 8280 Fürstenfeld, Austria
18
Department for Internal Medicine, Klinikum Klagenfurt am Wörthersee, 9020 Pörtschach am Wörthersee, Austria
19
Hospital Universitario Virgen del Rocio, 41013 Sevilla, Spain
20
Hospital del Mar, 08003 Barcelona, Spain
21
Hospital Son Llatzer, 07198 Palma de Mallorca, Spain
22
Hospital Universitario, 15006 A Coruña, Spain
23
Hospital de la Santa Creu i Sant Pau, 08026 Barcelona, Spain
24
Hospital Universitario de la Ribera, 46600 Alzira, Spain
25
Hospital Universitario de Salamanca, 37007 Salamanca, Spain
26
Centre Hospitalier Universitaire, 49100 Angers, France
27
Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, 1090 Vienna, Austria
28
3rd Med. Department, Paracelsus Medical University, 5020 Salzburg, Austria
29
Salzburg Cancer Research Institute, 5020 Salzburg, Austria
30
Cancer Cluster Salzburg, 5020 Salzburg, Austria
31
Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), 5020 Salzburg, Austria
*
Authors to whom correspondence should be addressed.
Academic Editors: Geoffrey Brown and Ewa Marcinkowska
Received: 10 February 2017 / Revised: 20 March 2017 / Accepted: 6 April 2017 / Published: 14 April 2017
(This article belongs to the Special Issue The Biology and Treatment of Myeloid Leukaemias)
View Full-Text   |   Download PDF [1527 KB, uploaded 14 April 2017]   |  

Abstract

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3–9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL. View Full-Text
Keywords: acute erythroleukemia; azacitidine; decitabine acute erythroleukemia; azacitidine; decitabine
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Almeida, A.M.; Prebet, T.; Itzykson, R.; Ramos, F.; Al-Ali, H.; Shammo, J.; Pinto, R.; Maurillo, L.; Wetzel, J.; Musto, P.; Van De Loosdrecht, A.A.; Costa, M.J.; Esteves, S.; Burgstaller, S.; Stauder, R.; Autzinger, E.M.; Lang, A.; Krippl, P.; Geissler, D.; Falantes, J.F.; Pedro, C.; Bargay, J.; Deben, G.; Garrido, A.; Bonanad, S.; Diez-Campelo, M.; Thepot, S.; Ades, L.; Sperr, W.R.; Valent, P.; Fenaux, P.; Sekeres, M.A.; Greil, R.; Pleyer, L. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. Int. J. Mol. Sci. 2017, 18, 837.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top